After stopping tirzepatide (Zepbound) three weeks ago, why am I experiencing dizziness on standing or bending over, and how should I manage it?

Orthostatic Hypotension After Tirzepatide Discontinuation

Your dizziness upon standing and bending over three weeks after stopping Zepbound (tirzepatide) most likely represents orthostatic hypotension, which can persist after GLP-1/GIP agonist discontinuation due to autonomic dysregulation, volume depletion, or unmasking of underlying cardiovascular conditions.

Understanding Your Symptoms

Your symptoms—dizziness when rising in the morning and with positional changes—are classic for orthostatic hypotension (OH), defined as a blood pressure drop of ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes of standing 1. These symptoms typically develop upon standing, are relieved by sitting or lying down, and are often worse in the morning 1.

While tirzepatide itself can cause hypotension during active treatment 1, the persistence of symptoms three weeks after discontinuation suggests several possibilities:

• Delayed autonomic recovery: GLP-1/GIP agonists can affect cardiovascular autonomic function, and tirzepatide has been reported to exacerbate orthostatic intolerance and cause marked tachycardia in susceptible patients 2
• Volume depletion: If you experienced significant GI side effects (nausea, vomiting, diarrhea) before or after stopping tirzepatide, this could have caused electrolyte imbalances and volume depletion 3, 4
• Unmasking of underlying conditions: The medication may have been masking pre-existing orthostatic intolerance or POTS (Postural Orthostatic Tachycardia Syndrome) 2

Immediate Assessment Steps

Confirm orthostatic hypotension with proper measurement 1:

• Measure blood pressure supine (lying down for 5 minutes)
• Then measure standing blood pressure at 1 and 3 minutes
• A drop of ≥20 mmHg systolic or ≥10 mmHg diastolic confirms OH 1
• Note your heart rate response: an excessive increase (>30 bpm) suggests POTS rather than pure OH 1

Assess for volume depletion and electrolyte disturbances 3, 4:

• Check for recent weight loss, decreased fluid intake, or ongoing GI symptoms
• Obtain basic metabolic panel to evaluate potassium, magnesium, and calcium levels
• Severe electrolyte disturbances from tirzepatide-induced GI effects can cause life-threatening arrhythmias 4

Rule out cardiac causes 1:

• If you have risk factors for cardiovascular disease, consider ECG to exclude arrhythmias
• Bradyarrhythmias, tachyarrhythmias, and structural heart disease can present with orthostatic symptoms 1

Management Approach

Non-Pharmacologic Interventions (First-Line)

Increase fluid and salt intake 1:

• Target 2-3 liters of fluid daily
• Increase dietary sodium unless contraindicated by hypertension or heart failure
• This addresses potential volume depletion from recent tirzepatide use

Physical countermeasures 1:

• Rise slowly from lying to sitting, then sitting to standing
• Perform leg crossing, squatting, or muscle tensing before standing
• Elevate the head of your bed 10-20 degrees to reduce nocturnal diuresis

Compression garments 1:

• Waist-high compression stockings (30-40 mmHg) can reduce venous pooling
• Particularly helpful if symptoms persist despite conservative measures

When to Seek Urgent Evaluation

Seek immediate medical attention if you experience 1:

• Syncope (actual loss of consciousness)
• Chest pain, palpitations, or severe shortness of breath
• Signs of poor organ perfusion (confusion, decreased urine output, severe fatigue)
• Blood pressure <80 mmHg systolic 1

Medication Review

Evaluate all current medications 1:

• Diuretics, alpha-blockers, and other antihypertensives can worsen OH 1
• If you're on blood pressure medications, these may need adjustment now that tirzepatide is discontinued 1
• Avoid NSAIDs and other nephrotoxic drugs that could worsen volume status 3

Special Considerations

If symptoms persist beyond 4-6 weeks 1:

• Consider formal autonomic testing with tilt-table test
• Evaluate for delayed orthostatic hypotension (occurring >3 minutes after standing) 1
• Screen for underlying autonomic failure, especially if you have diabetes or Parkinson's disease 1

Consider POTS if 1, 2:

• You experience marked heart rate increase (>30 bpm) with standing
• Symptoms include palpitations, tremor, and generalized weakness
• You're a younger woman, as POTS predominantly affects this demographic 1
• Tirzepatide has been reported to exacerbate POTS symptoms 2

Prognosis and Follow-Up

Most cases of medication-related orthostatic hypotension improve within weeks of drug discontinuation once volume status normalizes and autonomic function recovers 1. However, persistent symptoms warrant further cardiovascular and autonomic evaluation 1.

Monitor for 1:

• Improvement in symptoms with conservative measures over 2-4 weeks
• Need for formal autonomic testing if symptoms persist
• Development of new symptoms suggesting alternative diagnoses

The key is distinguishing between transient post-medication effects versus unmasking of underlying autonomic dysfunction that requires long-term management 1, 2.